The healthcare sector has achieved new heights leveraging technology, but cancer has still remained a hurdle to trouble the scientists. According to Statista, almost 1.74 million new cancer cases were found in the U.S in 2018. This massive leap in the numbers of affected patients has propelled the scientists to excavate the unknown areas, and as a consequence, the oncological medicine market has gained exponential leap. Statista states that the expenditure on global oncology market will escalate from $81 billion in 2017 to $130 billion in 2022.
Propanc Biopharma, Inc., a biopharmaceutical company, aims at metamorphose the cancer treatment process through innovative discoveries, and their main focus lies on the eradication of cancer stem cells to help the patients suffering from solid tumors like pancreatic, ovarian, and colorectal cancers. The company has signed a cooperation agreement to start the co-funded POP1 drug discovery program aimed at empowering Propanc’s main product, PRP, through the development of proper compound in order to provide proper treatment at the early stage. PRP, a combination of trypsinogen and chymotrypsinogen, attempts to prevent the metastasis which takes place due to Epithelial-Mesenchymal Transition (EMT), an internal cell program allowing the cancer cells to spread and grow on a rapid scale. In 2017, the U.S. Food and Drug Administration (FDA) provided Propanc's pancreatic cancer treatment with Orphan Drug Designation.
This integration will further involve Granada and Almeira hospitals, two important members of FIBAO, aPublic HealthOrganization which forwards helping hands in the development and commercialization of healthcare products having the potential to revamp the conventional notion.
One of the main hurdles of cancer treatment is the side effects, and Propanc has long been trying to cut short this problem. Under this agreement, the company will have proper assistance from the researchers of Granada and Jaen universities to achieve this goal. Previously, Propanc picked up LaVoieHealthScience, a public relation agency, as their integrated communications partner to escalate corporate awareness. Propanc has long been a serious and one of the most important players in the field of innovative cancer treatment, and this partnership will enormously be helpful to lead the whole process more precisely.